Biocompatible carbonized iodine-doped dots for contrast-enhanced CT imaging

다국어 초록 (Multilingual Abstract)

Background: Computed tomography (CT) imaging has been widely used for the diagnosis and surveillance of diseases. Although CT is attracting attention due to its reasonable price, short scan time, and excellent diagnostic ability, there are severe drawbacks of conventional CT contrast agents, such as low sensitivity, serious toxicity, and complicated synthesis process. Herein, we describe iodine-doped carbon dots (IDC) for enhancing the abilities of CT contrast agents. Method: IDC was synthesized by one-pot hydrothermal synthesis for 4 h at 180 ᕑ and analysis of its structure and size distribution with UV–Vis, XPS, FT-IR, NMR, TEM, and DLS. Furthermore, the CT values of IDC were calculated and compared with those of conventional CT contrast agents (Iohexol), and the in vitro and in vivo toxicities of IDC were determined to prove their safety. Results: IDC showed improved CT contrast enhancement compared to iohexol. The biocompatibility of the IDC was verified via cytotoxicity tests, hemolysis assays, chemical analysis, and histological analysis. The osmotic pressure of IDC was lower than that of iohexol, resulting in no dilution-induced contrast decrease in plasma. Conclusion: Based on these results, the remarkable CT contrast enhancement and biocompatibility of IDC can be used as an effective CT contrast agent for the diagnosis of various diseases compared with conventional CT contrast agents.

참고문헌 (Reference)

1 Lusic H, "X-ray-computed tomography contrast agents" 113 (113): 1641-1666, 2013

2 Idée J-M, "Use of Lipiodol as a drug-delivery system for transcath-eter arterial chemoembolization of hepatocellular carcinoma : a review" 88 (88): 530-549, 2013

3 Cheheltani R, "Tunable, biodegradable gold nanoparticles as contrast agents for computed tomography and photoacoustic imaging" 102 : 87-97, 2016

4 Hasebroock KM, "Toxicity of MRI and CT contrast agents" 5 (5): 403-416, 2009

5 Yohan Jeong ; 황희숙 ; 나건, "Theranostics and contrast agents for magnetic resonance imaging" 한국생체재료학회 22 (22): 159-171, 2018

6 Jost G, "The impact of the viscosity and osmolality of iodine contrast agents on renal elimination" 45 (45): 255-261, 2010

7 Zhao HY, "Synthesis and applica-tion of strawberry-like Fe3O4-Au nanoparticles as CT-MR dual-modality contrast agents in accurate detection of the progressive liver disease" 51 : 194-207, 2015

8 Ghann WE, "Syntheses and characterization of lisinopril-coated gold nanoparticles as highly stable targeted CT contrast agents in cardiovascular diseases" 28 (28): 10398-10408, 2012

9 Tian B, "Renal-Clearable Nickel-Doped Carbon Dots with Boosted Photothermal Conversion Efficiency for Multimodal Imaging-Guided Cancer Therapy in the Second Near-Infrared Biowindow" 31 (31): 2100549-, 2021

10 Su Y, "Renal clearable Hafnium-doped carbon dots for CT/Fluorescence imaging of orthotopic liver cancer" 255 : 120110-, 2020

11 Sendeski MM, "Pathophysiology of renal tissue damage by iodinated contrast media" 38 (38): 292-299, 2011

12 Schaefer-Prokop C, "New imaging techniques in the treatment guidelines for lung cancer" 19 (19): 71-83, 2002

13 Faucon A-L, "Nephrotoxicity of iodinated contrast media : From pathophysiology to prevention strategies" 116 : 231-241, 2019

14 Kistner A, "Negative effects of iodine-based contrast agent on renal function in patients with moderate reduced renal function hospitalized for COVID-19" 22 (22): 1-10, 2021

15 Shilo M, "Nanoparticles as computed tomography contrast agents : current status and future perspectives" 7 (7): 257-269, 2012

16 Lee N, "Nano-sized CT contrast agents" 25 (25): 2641-2660, 2013

17 Ibrahim Fatih Cengiz ; Joaquim Miguel Oliveira ; Rui L. Reis, "Micro-CT – a digital 3D microstructural voyage into scaffolds: a systematic review of the reported methods and results" 한국생체재료학회 22 (22): 279-289, 2018

18 Trang Huyen Le Kim ; 전휘석 ; 김진호 ; 박근칠 ; 김지선 ; 남윤성, "Lipiodol nanoemulsions stabilized with polyglycerol-polycaprolactone block copolymers for theranostic applications" 한국생체재료학회 21 (21): 204-213, 2017

19 Srivastava I, "Influence of electron acceptor and electron donor on the photophysical properties of carbon dots : a comparative investigation at the bulk-state and single-particle level" 29 (29): 1902466-, 2019

20 Shin H, "In situ vaccination with biocompatibility controlla-ble immuno-sensitizer inducing antitumor immunity" 197 : 32-40, 2019

21 Bolognese L, "Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percu-taneous coronary intervention(from the Contrast Media and Nephro-toxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial)" 109 (109): 67-74, 2012

22 Mollet NR, "High-resolution spiral computed tomography coronary angiogra-phy in patients referred for diagnostic conventional coronary angiogra-phy" 112 (112): 2318-2323, 2005

23 Xi D, "Gold nanoparticles as comput-erized tomography(CT)contrast agents" 2 (2): 12515-12524, 2012

24 Gierada DS, "Gadolinium as a CT contrast agent : assessment in a porcine model" 210 (210): 829-834, 1999

25 Jeong Y, "Facile Hydrothermal Synthesis of an Iodine-Doped Computed Tomography Contrast Agent Using Insoluble Triiodobenzene" 6 (6): 6961-6970, 2020

26 Almen T, "Experimental investigations with iohexol and their clinical relevance" 366 : 9-19, 1983

27 Ghaghada KB, "Evaluation of tumor microenvironment in an animal model using a nanoparticle contrast agent in computed tomography imaging" 18 (18): 20-30, 2011

28 Koç MM, "Evaluation of X-ray tomography contrast agents : A review of production, protocols, and biological appli-cations" 82 (82): 812-848, 2019

29 Tepel M, "Contrast-induced nephropathy : a clinical and evidence-based approach" 113 (113): 1799-1806, 2006

30 Davenport MS, "Contrast material–induced nephrotoxicity and intravenous low-osmo-lality iodinated contrast material : risk stratification by using estimated glomerular filtration rate" 268 (268): 719-728, 2013

31 Kishimoto M, "Comparison of excretory urographic contrast effects of dimeric and monomeric non-ionic iodinated contrast media in dogs" 69 (69): 713-715, 2007

32 Pasternak JJ, "Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents : a primer for the non-radiologist" Elsevier 87 (87): 390-402, 2012

33 Yang S-T, "Carbon dots as non-toxic and high-performance fluorescence imaging agents" 113 (113): 18110-18114, 2009

34 Fu J-J, "Bismuth chelate as a contrast agent for X-ray computed tomography" 18 (18): 1-10, 2020

35 Dias C, "Biocompatibility and bioimaging potential of fruit-based carbon dots" 9 (9): 199-, 2019

36 River C, "BALB/C mouse hematology"

37 Robison L, "A bismuth metal–organic framework as a contrast agent for X-ray computed tomography" 2 (2): 1197-1203, 2019